Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Early sCD8 plasma levels during subcutaneous rIl-2 therapy in patients with renal cell carcinoma correlate with response.

Literature DB >> 8494709

Early sCD8 plasma levels during subcutaneous rIl-2 therapy in patients with renal cell carcinoma correlate with response.

A Martens¹, R A Janssen, D T Sleijfer, A A Heijn, N H Mulder, T H The, L de Leij.

Abstract

Plasma sIl-2R and sCD8 levels of 12 patients with renal cell carcinoma were determined before and during subcutaneous rIl-2 therapy. Patients with a complete/partial remission showed a significantly stronger initial increase of sCD8 compared to patients with stable disease or tumour progression.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 1993 PMID： 8494709 PMCID： PMC1968458 DOI： 10.1038/bjc.1993.205

Source DB: PubMed Journal: Br J Cancer ISSN： 0007-0920 Impact factor: 7.640

14 in total

1. Soluble CD8 during T cell activation.

Authors: B E Tomkinson; M C Brown; S H Ip; S Carrabis; J L Sullivan
Journal: J Immunol Date: 1989-04-01 Impact factor: 5.422

2. Interleukin-2 with and without LAK cells in metastatic renal cell carcinoma: the Lyon first-year experience in 20 patients.

Authors: T Philip; A Mercatello; S Negrier; I Philip; P Rebattu; P Kaemmerlin; M Gaspard; E Tognier; V Combaret; J T Bijmann
Journal: Cancer Treat Rev Date: 1989-06 Impact factor: 12.111

Review 3. The biochemistry, biology, and role of interleukin 2 in the induction of cytotoxic T cell and antibody-forming B cell responses.

Authors: J J Farrar; W R Benjamin; M L Hilfiker; M Howard; W L Farrar; J Fuller-Farrar
Journal: Immunol Rev Date: 1982 Impact factor: 12.988

4. In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration.

Authors: M T Lotze; M C Custer; S O Sharrow; L A Rubin; D L Nelson; S A Rosenberg
Journal: Cancer Res Date: 1987-04-15 Impact factor: 12.701

5. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis.

Authors: D T Sleijfer; R A Janssen; J Buter; E G de Vries; P H Willemse; N H Mulder
Journal: J Clin Oncol Date: 1992-07 Impact factor: 44.544

6. Function of the CD4 and CD8 molecules on human cytotoxic T lymphocytes: regulation of T cell triggering.

Authors: B Fleischer; H Schrezenmeier; H Wagner
Journal: J Immunol Date: 1986-03-01 Impact factor: 5.422

7. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

Authors: S A Rosenberg; M T Lotze; L M Muul; A E Chang; F P Avis; S Leitman; W M Linehan; C N Robertson; R E Lee; J T Rubin
Journal: N Engl J Med Date: 1987-04-09 Impact factor: 91.245

2. Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-alpha-2 in combination with 5-FU.

Authors: B Göhring; D Riemann; U Rebmann; H Heynemann; J Schabel; J Langner
Journal: Urol Res Date: 1996

Review 3. Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors: Ruth Whittington; Diana Faulds
Journal: Drugs Date: 1993-09 Impact factor: 9.546

3 in total